Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
Terguride, the C9-10 dihydrogenated derivative of lisuride, is a new drug which inhibits pituitary prolactin (PRL) secretion. It has mixed dopaminergic-antidopaminergic and alpha 2-antiadrenergic activity, and has proved useful in the clinical management of hyperprolactinemia. However, no trial comp...
Hlavní autoři: | Ciccarelli, E, Touzel, R, Besser, M, Grossman, A |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
1988
|
Podobné jednotky
-
The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
Autor: Grossman, A, a další
Vydáno: (1987) -
Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study.
Autor: Verhelst, J, a další
Vydáno: (1991) -
Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
Autor: Marianne F. Clausen, a další
Vydáno: (2021-12-01) -
DEPOT BROMOCRIPTINE IN THE TREATMENT OF PROLACTINOMAS AND ACROMEGALY
Autor: Grossman, A, a další
Vydáno: (1985) -
Depot-bromocriptine treatment for prolactinomas and acromegaly.
Autor: Grossman, A, a další
Vydáno: (1986)